ETF Holdings Breakdown of MRSN

News associated with MRSN

Renaissance Technologies LLC Acquires 113,566 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN)

Renaissance Technologies LLC lifted its holdings in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) by 23.0% during the 4th quarter, Holdings Channel reports. The firm owned 606,285 shares of the company’s stock after purchasing an additional 113,566 shares during the quarter. Renaissance Technologies LLC’s holdings in Mersana Therapeutics were worth $867,000 at the […] - 2025-05-02 08:54:49

XTX Topco Ltd Reduces Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN)

XTX Topco Ltd trimmed its position in Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) by 81.7% during the 4th quarter, HoldingsChannel reports. The firm owned 63,530 shares of the company’s stock after selling 283,725 shares during the period. XTX Topco Ltd’s holdings in Mersana Therapeutics were worth $91,000 as of its most recent filing with […] - 2025-04-30 08:31:04

ExodusPoint Capital Management LP Buys Shares of 194,153 Mersana Therapeutics, Inc. (NASDAQ:MRSN)

ExodusPoint Capital Management LP bought a new position in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 194,153 shares of the company’s stock, valued at approximately $278,000. ExodusPoint Capital Management LP […] - 2025-04-14 07:46:54

Los Angeles Capital Management LLC Sells 29,900 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN)

Los Angeles Capital Management LLC lowered its holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) by 15.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 159,760 shares of the company’s stock after selling 29,900 shares during the […] - 2025-03-05 10:46:57

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $5.57 Consensus Price Target from Analysts

Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) has earned an average rating of “Moderate Buy” from the nine brokerages that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The […] - 2025-02-19 06:12:53

China Universal Asset Management Co. Ltd. Buys Shares of 26,194 Mersana Therapeutics, Inc. (NASDAQ:MRSN)

China Universal Asset Management Co. Ltd. purchased a new stake in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 26,194 shares of the company’s stock, valued at approximately $37,000. A number of other hedge funds have also […] - 2025-02-05 08:46:56

MRSN institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-05-08	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	163,327	USD 54,715
2025-05-08	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	55,170	USD 18,482
2025-05-08	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	55,170	USD 18,482 3.1%
Total =		273,667	USD 91,679

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer